485 ROUTE 1 SOUTH, ISELIN, NJ
Provides Update on Type A Meeting with FDA
Changes in Board, Management or Compensation
Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Earnings Release
News, Material Contracts
Other Events
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Q3
Q1
Amended Annual Report
FY 2024
Q2
FY 2023 amended
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership